Business Wire

Helical Fusion and National Institute for Fusion Science Establish 'HF Collaboration Research Group' and Dedicated Experimental Space for Early Commercial Fusion Reactor Deployment

Share

Helical Fusion has entered a partnership agreement with the National Institute for Fusion Science (NIFS) in March 2024. NIFS has established the "HF Collaboration Research Group" with activities starting in April, special experimental research space has been dedicated onsite at NIFS, which already houses the world's largest superconductor and fusion experimental facility, for Helical Fusion.
With its support from NIFS, Helical Fusion will accelerate the realization of the world's first commercial fusion reactor.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240507957768/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Co-Founder, CEO of Helical Fusion Takaya Taguchi (left) and Chief of Industry-Academia-Government Coordination Section of NIFS Ryo Yasuhara (right), shake hands at NIFS in Toki-City, Gifu, Japan. (Photo: Business Wire)

[Background]
Against the backdrop of a projected global population increase of ~1.7 billion by 2050* and the corresponding surge in worldwide electricity demand, conventional power generation methods alone are expected to struggle to meet these needs. Fusion power offers a clean and safe alternative, utilizing inexhaustible fuel supplies, such as seawater, and thus holds the promise as a technology capable of fundamentally addressing these global challenges. With Japan's energy self-sufficiency rate at a low of 13.3% and fossil fuel dependency still exceeding 80%**, research and development efforts have been underway to secure future baseload power sources.

NIFS, boasting one of the world's largest fusion experimental facilities, the Large Helical Device (LHD) in Gifu prefecture, Japan, has been at the forefront of research into helical-type fusion reactors since its establishment by the government in 1989, yielding remarkable results on a global scale. Building on NIFS's expertise, Helical Fusion was founded in 2021, leveraging the speed and agility typical of startups to lead the development of the world's first commercial steady fusion reactor.

While individual collaborative research efforts have been ongoing with NIFS, the firm establishment of the "HF Collaboration Research Group" going forward, as well as a dedicated experimental space, marks a significant step toward strengthening cooperation, aimed towards the early social implementation of fusion energy.
Reference: for the press release from the National Institute for Fusion Science, click here)

[Comment from Mr. Takaya TAGUCHI (Co-founder, CEO of Helical Fusion)]
Helical Fusion is a startup born from the wealth of cutting-edge research achievements and expertise accumulated by NIFS over more than 30 years. We have conducted numerous joint research projects with NIFS in areas such as high-temperature superconducting magnets and liquid metal blankets. Given the growing global expectations of the helical-stellarator fusion approach, to operate as a steady-state commercialized reactor, we have further strengthened our collaboration to accelerate development by establishing this department, as well as setting up dedicated experimental research space. This will not only accelerate joint research but also advance progress in our proprietary tech development, particularly in the field of high-temperature superconducting magnets. We express our feelings of appreciation to the NIFS team for their cooperation and strive to meet everyone's expectations by furthering our efforts in research and development, so as to lead development with global competition towards an operation ready, steady-state fusion reactor. Furthermore, we aim to contribute to the creation of industries where Japan's proud technologies, from basic research to high-end manufacturing, can be leveraged.

[Comment from Mr. Ryo Yasuhara (Chief of Industry-Academia-Government Coordination Section, NIFS)]
The National Institute for Fusion Science has established a collaborative research department with Helical Fusion, called the "HF Collaboration Research Group", in order to conduct research and development for the practical implementation of helical-type fusion reactors. This joint research group will mainly contribute the specialized knowledge and resources of Helical Fusion and NIFS to conduct research activities aimed at realizing helical-type fusion reactor. NIFS aims to contribute to the advancement of fusion science and the establishment of a broad foundation for science and technology through research activities at the highest global standards. We hope that the achievements obtained in this research group will be a step towards realizing sustainable energy.

*“World Energy Outlook 2023” International Energy Agency (https://www.iea.org/reports/world-energy-outlook-2023)
**”The white paper on energy usage 2022”, Agency for Natural Resources and Energy (https://www.enecho.meti.go.jp/about/whitepaper/2023/pdf/)

[About Us]
Helical Fusion is a Japanese start-up company aiming at the social implementation of fusion energy with a magnetic confinement fusion reactor.
Various fusion methods have been developed in the world over the past 60 years as a next generation energy source.
In Japan, the helical fusion method, which uses a superconducting helical coil with a double-helical structure similar to DNA to stably confine high-temperature plasma, has been developed and nurtured to a great extent. We are aiming to develop the world's first steady-state fusion reactor by incorporating more advanced technologies into the helical-stellarator type fusion reactor.
Additionally, Helical Fusion's proprietary development efforts, including high-temperature superconducting magnet vital for realizing commercial reactors, have received Japanese SBIR grant funding, further accelerating progress towards commercialization.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Helical Fusion Co., Ltd.
PR manager
E-mail: contact@helicalfusion.com
TEL: 81-50-5471-5890

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release

The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa

ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release

ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an

Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release

Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai

Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational

Perma-Pipe International Holdings, Inc. Announces Third Quarter Financial Results23.12.2024 18:43:00 CET | Press Release

Perma-Pipe International Holdings, Inc. (NASDAQ: PPIH) announced today financial results for the second quarter and fiscal year-to-date period ended October 31, 2024. "Net sales for the third quarter were $41.6 million, a decrease of $4.1 million, as compared to the same quarter last year. Net income attributable to common stock of $2.5 million was an increase of $0.5 million, or 29%, compared to $1.9 million in the third quarter of 2023. For the nine months ended October 31, 2024, net sales of $113.4 million represent an increase of 3% compared to the nine months ended October 31, 2023. The net income attributable to common stock of $7.2 million was an increase of $5.4 million, or 294%, compared to net income attributable to common stock of $1.8 million in the nine months ended October 31, 2023,” noted President and CEO David Mansfield. “Backlog in the third quarter shows considerable growth and now stands at $114.2 million. This is the equivalent to approximately nine months revenue

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye